The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

BTK inhibitors increase infection risk in B-cell lymphoma patients, necessitating proactive monitoring and prophylactic strategies. BTK inhibition affects immune functions, impairing pathogen ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the ...

Nurix Therapeutics (NRIX) has been able to post initial positive results from both of its early-stage studies using its protein degraders known as NX-2127 and NX-5948 for the treatment of patients ...

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL). The ...